Chronic neurodegenerative disorders including dementias, as Alzheimer's disease (AD) and movement disorders, as Parkinson's disease (PD) are strongly increasing worldwide. Up to now, very little is known about their biochemical mechanism and no effective therapeutic strategies are available to face brain functionality deterioration. A very intriguing hypothesis actively under investigation is referred as "microbiota-gut-brain axis". It suggests that human gut microbial community might impact central nervous system functionality through a bidirectional interaction that potentially might play also a key role in neurodegenerative disorders. Here we present a novel technological project, named MINERVA supported by the European Research Council (ERC) Programme, that aims, by using an innovative bioengineering approach, at evaluating microbiota impact on brain functionality. MINERVA goal is to develop a cutting edge technological platform, based on organ on chip microfluidic device, to model the main players of the microbiota-gut-brain axis. The final aim of MINERVA is to investigate the role of microbiota on brain functionality in physiological but also in pathological neurodegenerative conditions in order to improve the knowledge in the field and open the way to potential novel therapeutic microbiota-based approach for neurodegenerative disorders.
|Titolo:||MINERVA: The technological project to boost research on the microbiota-gut-brain axis in chronic neurodegenerative disorders|
|Data di pubblicazione:||2017|
|Appare nelle tipologie:||01.1 Articolo in Rivista|